Evidence check: VKORC1 in the context of Wechseljahre

The evidence for VKORC1 in the context of menopause is weak. VKORC1 encodes an enzyme that recycles vitamin K, which is crucial for blood coagulation and bone metabolism. During menopause, estrogen decline accelerates bone loss. Vitamin K activates osteocalcin, a bone-building protein. In theory, VKORC1 variants could affect vitamin K availability and thus influence osteoporosis risk. However, no strong human studies directly link VKORC1 polymorphisms to menopausal symptoms or bone density changes. The evidence is mechanistic at best. VKORC1 testing is primarily used for warfarin dosing, not menopause management. Relying solely on a VKORC1 DNA result without clinical markers (e.g., vitamin K levels, bone density) is not actionable. For personalized advice during menopause, consult a specialist. Evidence level: unclear/mechanistic.